Rational Dose Selection for a Nonnucleoside Reverse Transcriptase Inhibitor through Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation

Por Drusano, G. L., Moore, K. H. P., Kleim, J. P., Prince, W., Bye, A.
Publicado em 2002

Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.

Por Balzarini, J, Karlsson, A, Meichsner, C, Paessens, A, Riess, G, De Clercq, E, Kleim, J P
Publicado em 1994

Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence...

Por Kleim, J P, Rösner, M, Winkler, I, Paessens, A, Kirsch, R, Hsiou, Y, Arnold, E, Riess, G
Publicado em 1996

Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication.

Por Kleim, J P, Bender, R, Billhardt, U M, Meichsner, C, Riess, G, Rösner, M, Winkler, I, Paessens, A
Publicado em 1993

Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline...

Por Pelemans, H, Esnouf, R, Dunkler, A, Parniak, M A, Vandamme, A M, Karlsson, A, De Clercq, E, Kleim, J P, Balzarini, J
Publicado em 1997

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.

Por Kleim, J P, Bender, R, Kirsch, R, Meichsner, C, Paessens, A, Rösner, M, Rübsamen-Waigmann, H, Kaiser, R, Wichers, M, Schneweis, K E
Publicado em 1995